title: Dosimetric parameters as predictive factors for biochemical control in patients with higher risk prostate cancer treated with Pd-103 and supplemental beam radiation.
abstract: OBJECTIVE
  To analyze the role of dosimetric quality parameters in maximizing cancer eradication in higher risk prostate cancer patients treated with palladium (Pd)-103 and supplemental beam radiation.
  
  
  METHODS
  One-hundred-seventy-nine patients treated with Pd-103 and supplemental beam radiation, with minimum 2 years follow-up prostate-specific antigen (PSA) values and posttreatment computed tomography scans were analyzed. Dosimetric parameters included the V100 (percent of the postimplant volume covered by the prescription dose), the D90 (the minimum dose that covered 90% of the post implant volume), and the treatment margins (the radial distance between the prostatic edge and the prescription isodose). Treatment margins (TMs) were calculated using premarket software.
  
  
  RESULTS
  Freedom from biochemical failure was 79% at 3 years, with 92 of the 179 patients (51%) followed beyond 3 years. In comparing patients who did or did not achieve biochemical control, the most striking differences were in biologic factors of pretreatment PSA and Gleason score. The V100, D90, and average TM all showed nonsignificant trends to higher values in patients with biochemical control. In multivariate analysis of each of the three dosimetric parameters against PSA and Gleason score, TM showed the strongest correlation with biochemical control (p = 0.19).
  
  
  CONCLUSIONS
  For patients with intermediate and high-risk prostate cancer treated with Pd-103 brachytherapy and external beam radiation, biologic factors (PSA and Gleason score) were the most important determinants of cancer eradication. However, there is a trend to better outcomes among patients with higher quality implant parameters, suggesting that attention to implant quality will maximize the likelihood of cure.
authors.affiliation: Department of Radiation Oncology, University of Washington, Seattle, WA, USA.
authors.forename: Peter
authors.initials: P
authors.lastname: Orio
authors.forename: Kent
authors.initials: K
authors.lastname: Wallner
authors.forename: Gregory
authors.initials: G
authors.lastname: Merrick
authors.forename: Andrew
authors.initials: A
authors.lastname: Herstein
authors.forename: Paul
authors.initials: P
authors.lastname: Mitsuyama
authors.forename: Ken
authors.initials: K
authors.lastname: Thornton
authors.forename: Wayne
authors.initials: W
authors.lastname: Butler
authors.forename: Steven
authors.initials: S
authors.lastname: Sutlief
mesh_terms: D001918:Brachytherapy / Q000379:methods* / Q000592:standards; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D015999:Multivariate Analysis; D010165:Palladium / Q000627:therapeutic use*; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000401:mortality / Q000532:radiotherapy*; D011868:Radioisotopes / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D014057:Tomography, X-Ray Computed
chemical_list: D011868:Radioisotopes; D010165:Palladium; D017430:Prostate-Specific Antigen